Pilot Study of REGN5678 for High-Risk Prostate Cancer
This study is looking at the safety and effects of a drug called REGN5678 in men with high-risk, localized prostate cancer. You might be able to join if you are a man aged 18 or older with a specific type of prostate cancer (Gleason 8 or greater) confirmed by a recent biopsy. The study will also use another drug, Piflufolastat F18, given through an IV. Researchers will measure any side effects to see how safe REGN5678 is. They will also look at how many patients show a positive response in their cancer after treatment. The current status of this study is unclear, and it plans to enroll 42 participants.
- Study design
- This is an interventional study with a planned enrollment of 42 participants. The phase of the study is not specified.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety will be monitored through study completion, which is an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT06085664
A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
Recruiting
PHASE1Ages 18+InterventionalTreatmentM.D. Anderson Cancer CenterInvestigator-initiated
~42 participants
Updated 2026-08-25 on ClinicalTrials.gov
What's tested:REGN5678Piflufolastat F18
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Measured over Through study completion; an average of 1 year
Conditions
Where it's being run
1 sites across 1 statesTexas1
Study leadership
- Sumit K Subudhi, MD, PHD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Men ≥ 18 years of age
Histologically documented Gleason 8 or greater prostatic adenocarcinoma in at least 3 biopsy cores and at least 8 mm of disease on a single core of Gleason 8 or greater. Prostate biopsy within 3 months of screening is allowed for entry requirements. Prostate biopsy must be reviewed at MD Anderson Cancer Center. Patients with small cell, neuroendocrine, or transitional cell carcinomas or mixed histologies are not eligible
Eastern Cooperative Oncology Group (ECOG) performance status (PS) grade of 0 or 1
No evidence of metastatic disease as documented by technetium-99m (99mTc) bone scan and by computed tomography (CT) or magnetic resonance imaging (MRI) scans. Imaging may be obtained up to 60 days prior to enrollment
Localized or locally advanced disease deemed by the surgeon to be resectable. Patients must be appropriate candidates for radical prostatectomy plus pelvic lymph node dissection
No prior treatment for prostate cancer including prior surgery (excluding transurethral resection of the prostate \[TURP\]), cryoablation, pelvic lymph node dissection, radiation therapy, hormonal therapy or chemotherapy
Hemoglobin ≥ 11 g/dL
Absolute neutrophil count ≥ 1.5 x 10\^9/L
Platelet count ≥ 100 x 10\^9/L
Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or estimated glomerular filtration rate \> 50 mL/min/1.73 m\^2. A 24-hour urine creatinine collection may substitute for the calculated creatinine clearance to meet eligibility criteria
Total bilirubin ≤ 1.5 x ULN
NOTES: Patients with Gilbert's syndrome do not need to meet total bilirubin requirements provided their total bilirubin is not greater than their historical level. Gilbert's syndrome must be documented appropriately as past medical history
Aspartate aminotransferase (AST) ≤ 2.5 x ULN
Alanine aminotransferase (ALT) ≤ 2.5 x ULN
Alkaline phosphatase (ALP) ≤ 2.5 x ULN
Consent to MD Anderson laboratory protocol PA13-0291
Willing and able to comply with clinic visits and study-related procedures
Provide informed consent signed by study patient
To avoid risk of drug exposure through the ejaculate (even men with vasectomies), subjects must use a condom during sexual activity while on study drug and for 3 months following the last dose of study drug. If the subject is engaged in sexual activity with a woman of childbearing potential, a condom is required along with another effective contraceptive method consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies and their partners. Donation of sperm is not allowed while on study drug and for 3 months following the last dose of study drug
Exclusion
Prior hormone therapy for prostate cancer including orchiectomy, antiandrogens, ketoconazole, or estrogens (5-alpha reductase inhibitors allowed), or luteinizing hormone-releasing hormone (LHRH) agonists/antagonists
Currently enrolled in another interventional study
Concurrent treatment with systemic corticosteroids (prednisone dose \> 10 mg per day or equivalent) or other immunosuppressive drugs \< 14 days prior to treatment initiation. Steroids that are topical, inhaled, nasal (spray), or ophthalmic solution are permitted
History of or known or suspected autoimmune disease (exception\[s\]: subjects with vitiligo, resolved childhood atopic dermatitis, hypothyroidism, or hyperthyroidism that is clinically euthyroid at screening are allowed)
Known evidence of an active infection requiring systemic therapy such as human immunodeficiency virus (HIV), active hepatitis, or fungal infection. Patients with known HIV infection which is well-controlled (undetectable viral load by HIV ribonuclecid acid \[RNA\] polymerase chain reaction \[PCR\]) and CD4 counts greater than 350 are permitted to participate
History of clinically significant cardiovascular disease including, but not limited to:
Myocardial infarction or unstable angina ≤ 6 months prior to treatment initiation
Clinically significant cardiac arrhythmia
Deep vein thrombosis, pulmonary embolism, stroke ≤ 6 months prior to treatment initiation
Congestive heart failure (New York Heart Association class III-IV)
Pericarditis/clinically significant pericardial effusion
Myocarditis
Endocarditis
History of major implant(s) or device(s), including but not limited to:
Prosthetic heart valve(s)
Artificial joints and prosthetics placed ≤ 12 months prior to treatment initiation
Current or prior history of infection or other clinically significant adverse event associated with an exogenous implant or device that cannot be removed
Other prior malignancy (exceptions: adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently in complete remission) ≤ 2 years prior to enrollment
Has received major surgery within 14 days of first administration of study drug
Encephalitis, meningitis, neurodegenerative disease (with the exception of mild dementia that does not interfere with activities of daily living \[ADLs\]) or uncontrolled seizures in the year prior to first dose of study therapy
Known history of, or any evidence of interstitial lung disease, or active, non-infectious pneumonitis (past 5 years)
Receipt of a live vaccine within 4 weeks of planned start of study medication
Prior allogeneic stem cell transplantation or recipients of organ transplants at any time, or autologous stem cell transplantation within 12 weeks of the start of study treatment
Any medical, psychological or social condition that in the opinion of the investigator, would preclude participation in this study
What this trial measures
- Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0Through study completion; an average of 1 year